{
    "clinical_study": {
        "@rank": "95750", 
        "arm_group": [
            {
                "arm_group_label": "Placebo Cream", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Topically applied once daily"
            }, 
            {
                "arm_group_label": "Naftin 1% Cream", 
                "arm_group_type": "Experimental", 
                "description": "Topically applied once daily"
            }
        ], 
        "brief_summary": {
            "textblock": "To see how well Naftin 1% cream works when applied once daily to the affected area.  The\n      results will be compared to those using a placebo cream, which is a cream with no active\n      ingredient.  Safety will also be measured."
        }, 
        "brief_title": "Evaluation of Efficacy and Safety of Naftin 1% Cream in Adolescent Subjects With Tinea Cruris", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Tinea Cruris", 
            "Jock Itch"
        ], 
        "condition_browse": {
            "mesh_term": "Tinea"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Review and sign statement of Informed Consent and HIPAA authorization.\n\n          -  Males or non-pregnant females \u2265 12 years of age to 17 years, 11 months, of any race\n             or sex. Females of child-bearing potential must have a negative urine pregnancy test.\n\n          -  The parent/legal guardian must complete the informed consent process AND the subject\n             must complete the assent process and sign the appropriate form (if age appropriate).\n\n          -  Presence of tinea cruris characterized by clinical evidence of a tinea infection (at\n             least moderate erythema, moderate scaling, and mild pruritus) based on signs and\n             symptoms.\n\n          -  KOH positive baseline skin scrapings obtained from the site most severely affected or\n             a representative site of the overall severity.\n\n          -  Subjects must be in good health and free from any clinically significant disease that\n             might interfere with the study evaluations.\n\n          -  Subject must be able to understand the requirements of the study and willing to\n             comply with the study requirements.\n\n        Exclusion Criteria:\n\n          -  A life threatening condition (ex. autoimmune deficiency syndrome, cancer, unstable\n             angina, or myocardial infarction) within the last 6 months.\n\n          -  Subjects with abnormal findings - physical or laboratory - that are considered by the\n             investigator to be clinically important and indicative of conditions that might\n             complicate interpretation of study results.- Severe dermatophytoses, mucocutaneous\n             candidiasis, or bacterial skin infection.\n\n          -  Subjects with a known hypersensitivity to study medications or their components.\n\n          -  Subjects who have a recent history or who are currently known to abuse alcohol or\n             drugs.\n\n          -  Uncontrolled diabetes mellitus.\n\n          -  Hemodialysis or chronic ambulatory peritoneal dialysis therapy.\n\n          -  Current diagnosis of immunocompromising conditions.\n\n          -  Atopic or contact dermatitis.\n\n          -  Severe dermatophytoses, mucocutaneous candidiasis, or bacterial skin infection.\n\n          -  Female subject who is pregnant or lactating, who is not using or does not agree to\n             use an acceptable form of contraception during the study, or who intends to become\n             pregnant during the study (females who are surgically sterilized  for at least 2\n             years are not considered to be of childbearing potential).\n\n          -  Subjects using the following medications:\n\n               -  Topical anti-fungal therapy, powders or topical corticosteroids applied\n                  within 14 days prior to randomization. Terbinafine, butenafine, and naftifine\n                  (topical) within 30 days prior to randomization.\n\n               -  Oral anti-fungal therapies within 3 months of randomization (8 months for oral\n                  terbinafine).\n\n               -  Systemic antibiotic or corticosteroid treatment within 30 days of randomization.\n\n               -  Any other significant treatments, except hormonal contraception and\n                  multivitamin, at the discretion of the investigator that would interfere with\n                  study treatment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "65", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01885156", 
            "org_study_id": "MUS 90200_3028_1"
        }, 
        "intervention": [
            {
                "arm_group_label": "Naftin 1% Cream", 
                "description": "Topically applied once a day", 
                "intervention_name": "Naftin 1% Cream", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo Cream", 
                "description": "Topically applied once a day", 
                "intervention_name": "Placebo Cream", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Naftifine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 24, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Belize City", 
                        "country": "Belize"
                    }, 
                    "name": "Merz Investigational Site # 501001"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Belize City", 
                        "country": "Belize"
                    }, 
                    "name": "Merz Investigational Site # 501002"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Cristobal", 
                        "country": "Dominican Republic"
                    }, 
                    "name": "Merz Investigative Site # 180002"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santo Domingo", 
                        "country": "Dominican Republic"
                    }, 
                    "name": "Merz Investigative Site # 180001"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Pedro Sula", 
                        "country": "Honduras"
                    }, 
                    "name": "Merz Investigative Site # 504001"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Belize", 
                "Dominican Republic", 
                "Honduras"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of Naftin 1% Cream in Adolescent Subjects With Tinea Cruris", 
        "overall_official": {
            "affiliation": "Merz Pharmaceuticals, LLC", 
            "last_name": "Stefan Plaum, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "- Summarization of AEs (local and systemic)", 
            "measure": "Safety of Naftin\u00ae 1% Cream, applied once daily for 4 weeks, compared to vehicle for treatment of subjects with KOH positive symptomatic tinea cruris in adolescent subjects (aged 12 years to 17 years, 11 months).", 
            "safety_issue": "Yes", 
            "time_frame": "Week 6"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01885156"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Complete Cure based on:\n-Negative mycology results; absence (Grade 0) of erythema, scaling, and pruritis\nOther efficacy variables assessed at Week 2, Week 4, and Week 6:\nEffective treatment\nMycological cure\nClinical Success\nClinical Cure\nInvestigator Global Assessment\nSubject Satisfaction Assessment", 
            "measure": "Efficacy of Naftin\u00ae 1% Cream, applied once daily for 4 weeks, compared to vehicle for treatment of subjects with KOH and culture positive symptomatic tinea cruris in adolescent subjects (aged 12 years to 17 years, 11 months).", 
            "safety_issue": "No", 
            "time_frame": "Week 6"
        }, 
        "source": "Merz Pharmaceuticals, LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merz Pharmaceuticals, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}